A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

Project: Other project

Project Details

StatusActive
Effective start/end date2/27/202/26/25

Funding

  • Eli Lilly: $10,096.15